{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Sam Barratt, Julia A Bielicki, David Dunn, Saul N Faust, Adam Finn, Lynda Harper, Pauline Jackson, Mark D Lyttle, Colin VE Powell, Louise Rogers, Damian Roland, Wolfgang Stöhr, Kate Sturgeon, Elia Vitale, Mandy Wan, Diana M Gibb & Mike Sharland.

Sam Barratt ¹, Julia A Bielicki ², David Dunn ¹, Saul N Faust ³, Adam Finn ⁴, Lynda Harper ^1,†, Pauline Jackson ⁵, Mark D Lyttle ^5,6, Colin VE Powell ^7,8, Louise Rogers ⁹, Damian Roland ^10,11, Wolfgang Stöhr ¹, Kate Sturgeon ¹, Elia Vitale ², Mandy Wan ¹², Diana M Gibb ¹, Mike Sharland ^2,*

¹ MRC Clinical Trials Unit, University College London, London, UK
² Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s University of London, London, UK
³ NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK
⁴ Bristol Children’s Vaccine Centre, School of Population Health Sciences/School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
⁵ Emergency Department, Bristol Royal Hospital for Children, Bristol, UK
⁶ Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK
⁷ Paediatric Emergency Medicine Department, Sidra Medicine, Doha, The State of Qatar
⁸ School of Medicine, Cardiff University, Cardiff, UK
⁹ Research and Development Nursing Team, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK
¹⁰ Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, University Hospitals of Leicester NHS Trust, Leicester, UK
¹¹ SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK
¹² Evelina Pharmacy, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
^* Corresponding author Email: msharland@sgul.ac.uk

^† In memoriam

In memoriam

Declared competing interests of authors: David Dunn reports grants from the National Institute for Health Research during the conduct of the study (RP-PG-1212-20006). Saul N Faust reports personal fees or grants from AstraZeneca plc (Cambridge, UK)/Medimmune (Gaithersburg, MA, USA), Sanofi SA (Paris, France), Pfizer Inc. (New York, NY, USA), Seqirus UK Ltd (Maidenhead, UK), Sandoz (Holzkirchen, Germany), Merck KGAA (Darmstadt, Germany), GlaxoSmithKline plc (Brentford, UK) and Johnson & Johnson (Brunswick, NJ, USA) outside the submitted work. In addition, Saul N Faust received grants for contract commercial clinical trials, which were paid to Saul N Faust’s institution (with no personal payment of any kind). Last, Saul N Faust is a member of the Health Technology Assessment Commissioning Committee (2017–22). Adam Finn reports grants from GlaxoSmithKline plc, Pfizer Inc., Novavax (Gaithersburg, MA, USA), Sanofi Pasteur (Lyon, France), VBI Vaccines Inc. (Cambridge, MA, USA), Janssen Pharmaceuticals (Beerse, Belgium), Valneva SE (Saint-Herblain, France) and JITSUVAX outside the submitted work.